Leerink Partnrs Has Pessimistic Outlook of CMPX Q2 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Equities researchers at Leerink Partnrs cut their Q2 2025 earnings estimates for shares of Compass Therapeutics in a research note issued to investors on Tuesday, April 1st. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($0.17) for the quarter, down from their prior estimate of ($0.14). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Leerink Partnrs also issued estimates for Compass Therapeutics’ Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.66) EPS and FY2026 earnings at ($0.76) EPS.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

A number of other analysts have also recently commented on CMPX. Piper Sandler began coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Tuesday. HC Wainwright raised their price target on shares of Compass Therapeutics from $10.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday. Jefferies Financial Group upped their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. Finally, D. Boral Capital restated a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Tuesday. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $13.38.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $1.46 on Friday. The company has a market cap of $201.89 million, a price-to-earnings ratio of -3.95 and a beta of 1.19. The stock’s fifty day moving average price is $2.76 and its 200 day moving average price is $2.10. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08.

Institutional Trading of Compass Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its position in shares of Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after acquiring an additional 12,917 shares during the period. Independent Advisor Alliance acquired a new position in Compass Therapeutics in the 4th quarter worth about $26,000. BNP Paribas Financial Markets purchased a new position in Compass Therapeutics during the fourth quarter worth approximately $27,000. Intech Investment Management LLC acquired a new stake in Compass Therapeutics in the third quarter valued at approximately $30,000. Finally, Mariner LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $30,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.